Coeptis shops local for its 'university' CAR-T tech

21 September 2022
coeptis_therapeutics_large

Coeptis Therapeutics (OTC PINK: COEP) has raided the nearby University of Pittsburgh in the latest step towards realizing the company’s aim of disrupting conventional treatment paradigms.

The Pennsylvania, USA-based firm has announced an exclusive license deal with the university for the rights to a chimeric antigen receptor T cell (CAR-T) technology – SNAP-CAR –designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

"SNAP-CAR may offer the potential to mitigate the toxicity of CAR-T therapy by allowing clinicians to control the adaptor dose"Completion of the exclusive license agreement for SNAP-CAR follows Coeptis’ entry into an option agreement with the university, which was announced in May.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology